Impact of UGT2B7 and ABCC2 Genetic Polymorphisms on Mycophenolic Acid Metabolism in Chinese Renal Transplant Recipients

References

• Roth D , ColonaJ , BurkeGW , CiancioG , EsquenaziV , MillerJ . Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients . Transplantation65 ( 2 ), 248 – 252 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Bullingham RE , NichollsAJ , KammBR . Clinical pharmacokinetics of mycophenolate mofetil . Clin. Pharmacokinet.34 ( 6 ), 429 – 455 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Basu NK , KoleL , KubotaS , OwensIS . Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid inhibition by curcumin . Drug Metab. Dispos.32 , 768 – 773 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Xie XC , LiJ , WangHYet al. Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients . Acta Pharmacol. Sin.36 ( 5 ), 644 – 650 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Shipkova M , ArmstrongVW , OellerichM , WielandE . Acyl glucuronide drug metabolites: toxicological and analytical implications . Ther. Drug Monit.25 ( 1 ), 1 – 16 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Djebli N , PicardN , RérolleJP , Le MeurY , MarquetP . Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients . Pharmacogenet. Genomics17 ( 5 ), 321 – 330 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Naesens M , KuypersDR , VerbekeK , VanrenterghemY . Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients . Transplantation82 ( 8 ), 1074 – 1084 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Staatz CE , TettSE . Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients . Clin. Pharmacokinet.46 ( 1 ), 13 – 58 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Kuypers DR , VanrenterghemY , SquiffletJPet al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil . Ther. Drug Monit.25 ( 5 ), 609 – 622 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Guo D , PangLF , HanYet al. Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers . Eur. J. Clin. Pharmacol.69 ( 4 ), 843 – 849 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Burckart GJ , FiggWD2nd , BrooksMMet al. Multi-institutional study of outcomes after pediatric heart transplantation: candidate gene polymorphism analysis of ABCC2 . J. Pediatr. Pharmacol. Ther.19 ( 1 ), 16 – 24 ( 2014 ).
   PubMedGoogle Scholar
• Zhang WX , ChenB , JinZet al. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients . Xenobiotica38 ( 11 ), 1422 – 1436 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Miura M , KagayaH , SatohSet al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients . Ther. Drug Monit.30 , 559 – 564 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Miura M , SatohS , InoueKet al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients . Eur. J. Clin. Pharmacol.63 ( 12 ), 1161 – 1169 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Geng F , JiaoZ , DaoYJet al. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals . Clin. Chim. Acta413 ( 7–8 ), 683 – 690 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• González JR , ArmengolL , SoléXet al. SNPassoc: an R package to perform whole genome association studies . Bioinformatics23 ( 5 ), 644 – 645 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Wickham H . Ggplot2: Elegant Graphics for Data Analysis . Springer-Verlag , NY, USA ( 2009 ).
   Google Scholar
• Barraclough KA , LeeKJ , StaatzCE . Pharmacogenetic influences on mycophenolate therapy . Pharmacogenomics11 ( 3 ), 369 – 390 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Cilião HL , Camargo-GodoyRBO , de SouzaMFet al. Association of UGT2B7, UGT1A9, ABCG2, and IL23R polymorphisms with rejection risk in kidney transplant patients . J. Toxicol. Environ. Health A80 ( 13–15 ), 661 – 671 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Picard N , YeeSW , WoillardJBet al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics . Clin. Pharmacol. Ther.87 ( 1 ), 100 – 108 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Zhao W , FakhouryM , DeschênesGet al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients . J. Clin. Pharmacol.50 ( 11 ), 1280 – 1291 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Sandanaraj E , JadaSR , ShuXet al. Influence of UGT1A9 intronic I399C > T polymorphism on SN-38 glucuronidation in Asian cancer patients . Pharmacogenomics J.8 ( 3 ), 174 – 185 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Girard H , VilleneuveL , CourtMHet al. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver . Drug Metab. Dispos.34 ( 7 ), 1220 – 1228 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Yang CH , WengZJ , ChuangLY , YangCS . Identification of SNP–SNP interaction for chronic dialysis patients . Comput. Biol. Med.83 , 94 – 101 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• van Hest RM , van GelderT , BouwRet al. Time-dependent clearance of mycophenolic acid in renal transplant recipients . Br. J. Clin. Pharmacol.63 ( 6 ), 741 – 752 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• van Hest RM , MathotRA , PescovitzMD , GordonR , MamelokRD , van GelderT . Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients . J. Am. Soc. Nephrol.17 ( 3 ), 871 – 880 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• McLachlan AJ , PontLG . Drug metabolism in older people – a key consideration in achieving optimal outcomes with medicines . J. Gerontol. A. Biol. Sci. Med. Sci.67 ( 2 ), 175 – 180 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Vial Y , TodM , HorneckerMet al. In vitro influence of fatty acids and bilirubin on binding of mycophenolic acid to human serum albumin . J. Pharm. Biomed. Anal.54 ( 3 ), 607 – 609 ( 2011 ).
   PubMed Web of Science ®Google Scholar